Blurbs

Analysts Offer Insights on Healthcare Companies: Astria Therapeutics (ATXS) and Karuna Therapeutics (KRTX)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Astria Therapeutics (ATXSResearch Report) and Karuna Therapeutics (KRTXResearch Report) with bullish sentiments.

Astria Therapeutics (ATXS)

Ladenburg Thalmann & Co. analyst Michael Higgins maintained a Buy rating on Astria Therapeutics today and set a price target of $30.00. The company’s shares closed last Tuesday at $5.22.

According to TipRanks.com, Higgins is a 4-star analyst with an average return of 5.3% and a 30.4% success rate. Higgins covers the Healthcare sector, focusing on stocks such as Eiger Biopharmaceuticals, Zynerba Pharmaceuticals, and Armata Pharmaceuticals.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Astria Therapeutics with a $21.50 average price target, implying a 318.3% upside from current levels. In a report issued on July 28, H.C. Wainwright also reiterated a Buy rating on the stock with a $13.00 price target.

See the top stocks recommended by analysts >>

Karuna Therapeutics (KRTX)

In a report released yesterday, Jason McCarthy from Maxim Group maintained a Buy rating on Karuna Therapeutics, with a price target of $300.00. The company’s shares closed last Tuesday at $228.45.

According to TipRanks.com, McCarthy is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of -40.0% and a 13.3% success rate. McCarthy covers the Healthcare sector, focusing on stocks such as Brainstorm Cell Therapeutics, Brooklyn ImmunoTherapeutics, and SELLAS Life Sciences Group.

Currently, the analyst consensus on Karuna Therapeutics is a Strong Buy with an average price target of $239.31, a -2.6% downside from current levels. In a report issued on August 8, Citigroup also maintained a Buy rating on the stock with a $280.00 price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on ATXS:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More

Latest News Feed